Medicines & Healthcare products Regulatory Agency of United Kingdom (MHRA - UK) has renewed GMP Compliance Certificate for Kopran Ltd.’s two plant at its manufacturing site at Khopoli, District-Raigad, Maharashtra that it complies with the Principles and guidelines of Good Manufacturing practices laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended).

This development illustrates the company's commitment to work closely with the MHRA-UK and strive for 100 Percent cGMP Compliance at its manufacturing facilities.

Last month, Kopran released its financial results for the quarter that ended in June 2023. The net sales of the company were at INR 117 crore in June 2023 down 3.86 percent from INR 121.69 crore in June 2022 while quarterly net profit stood at INR 2.77 crore in June 2023 down 63.49 percent from INR 7.60 crore in June 2022.